Zobrazeno 1 - 10
of 102
pro vyhledávání: '"David Jayabalan"'
Autor:
Mateo Mejia Saldarriaga, Walaa Darwiche, David Jayabalan, Jorge Monge, Cara Rosenbaum, Roger N. Pearse, Ruben Niesvizky, Mark Bustoros
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Recent insight in the genomic landscape of newly diagnosed multiple myeloma (NDMM) and its precursor conditions, monoclonal gammopathy of uncertain significance (MGUS), and smoldering myeloma have allowed the identification of patients with precursor
Externí odkaz:
https://doaj.org/article/3cbfd49d5d464b6db6efc7e67308993a
Autor:
Rosalie G Waller, Todd M Darlington, Xiaomu Wei, Michael J Madsen, Alun Thomas, Karen Curtin, Hilary Coon, Venkatesh Rajamanickam, Justin Musinsky, David Jayabalan, Djordje Atanackovic, S Vincent Rajkumar, Shaji Kumar, Susan Slager, Mridu Middha, Perrine Galia, Delphine Demangel, Mohamed Salama, Vijai Joseph, James McKay, Kenneth Offit, Robert J Klein, Steven M Lipkin, Charles Dumontet, Celine M Vachon, Nicola J Camp
Publikováno v:
PLoS Genetics, Vol 14, Iss 2, p e1007111 (2018)
The high-risk pedigree (HRP) design is an established strategy to discover rare, highly-penetrant, Mendelian-like causal variants. Its success, however, in complex traits has been modest, largely due to challenges of genetic heterogeneity and complex
Externí odkaz:
https://doaj.org/article/56a1a4b3c7db428994e077fd4e8c5a93
Autor:
Sridhar Mani, Susan B. Horwitz, Gary Goldberg, Hayley McDaid, W. Griffith Humphreys, Carrie Xu, Donglu Zhang, Van T. Ly, Adriana Comprelli, Lisa Iacono, David Jayabalan, François André, Lionel Perrin, S. Nilgün Çömezoglu, Marvin Cohen, Sanjay Goel
Supplementary Data from The Effect of Ketoconazole on the Pharmacokinetics and Pharmacodynamics of Ixabepilone: A First in Class Epothilone B Analogue in Late-Phase Clinical Development
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::699687c0c30295f2d1de845abad7ce93
https://doi.org/10.1158/1078-0432.22439589
https://doi.org/10.1158/1078-0432.22439589
Autor:
Sridhar Mani, Susan B. Horwitz, Gary Goldberg, Hayley McDaid, W. Griffith Humphreys, Carrie Xu, Donglu Zhang, Van T. Ly, Adriana Comprelli, Lisa Iacono, David Jayabalan, François André, Lionel Perrin, S. Nilgün Çömezoglu, Marvin Cohen, Sanjay Goel
Purpose: To determine if ixabepilone is a substrate for cytochrome P450 3A4 (CYP3A4) and if its metabolism by this cytochrome is clinically important, we did a clinical drug interaction study in humans using ketoconazole as an inhibitor of CYP3A4.Exp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::859f1d308bd5da29c4621d29624d656f
https://doi.org/10.1158/1078-0432.c.6517026
https://doi.org/10.1158/1078-0432.c.6517026
Autor:
Lauren Reiman, Olivia Perez de Acha, David Jayabalan, Zachary Walker, Grace Bosma, Diana Abbott, Drew Ribadeneyra, Ruben Niesvizky, Tomer Mark, Peter Forsberg, Daniel Sherbenou
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:S53-S54
Autor:
Shebli Atrash, Philippe Thompson-Leduc, Ming-Hui Tai, Shuchita Kaila, Kathleen Gray, Isabelle Ghelerter, Marie-Hélène Lafeuille, David Jayabalan, Patrick Lefebvre, Adriana Rossi
Publikováno v:
Clinical lymphoma, myelomaleukemia. 22(8)
Daratumumab was approved for multiple myeloma (MM) in 2015. While its safety and efficacy are well documented, there is limited real-world information on its use and outcomes in patients of different races.We conducted a retrospective chart review of
Autor:
Duane C. Hassane, John Postley, Steven P. Salvatore, Ruben Niesvizky, Kseniya Petrova-Drus, David Jayabalan, Julia T. Geyer, Marc Braunstein, Yuliya Jhanwar, Roger N. Pearse, Adriana C Rossi, Karen L. Rech, Cara A. Rosenbaum
Publikováno v:
American Journal of Clinical Pathology. 154:767-775
Objectives Crystal-storing histiocytosis (CSH) is rare in plasma cell dyscrasias, with only 3 cases reported in the setting of amyloid. No cases of crystal-negative histiocytosis coincident with multiple myeloma and amyloidosis have been reported pre
Autor:
Krzysztof Jamroziak, Artur Jurczyszyn, Chor Sang Chim, Monika Długosz-Danecka, Deepu Madduri, Julia Kelman, Max Bittrich, Michel Delforge, Klaus Martin Kortüm, Gabor Mikala, Ariel Kleman, Jorge J. Castillo, Maria-Victoria Mateos, Adam J. Olszewski, Saurabh Chhabra, Pawel Robak, Lidia Usnarska-Zubkiewicz, Anna Waszczuk-Gajda, Iwona Hus, Sarah Goldman-Mazur, David Jayabalan, Julio Davila Valls, Irit Avivi, Rebecca Silbermann, Norbert Grząśko, Stuart L. Goldberg, David H. Vesole, Yael C Cohen, Ruben Niesvizky, Piotr Mazur, Anna Suska, Verónica González-Calle, Laura Rosiñol, Alessandro Gozzetti, Łukasz Szukalski, Jacek Czepiel, Jakub Radocha, Parameswaran Hari, Daniel Coriu, Izabela Kozłowska, Aimee Chappell, Peter Barth, Massimo Gentile
Publikováno v:
Leukemia & Lymphoma. 61:1885-1893
The MAF translocations, t(14;16) and t(14;20), are considered as adverse prognostic factors based on few studies with small sample sizes. We report on their prognostic impact in a large group of 254 patients - 223 (87.8%) with t(14;16) and 31 (12.2%)
Autor:
Kari Flicker, Angelique Boyer, Roger N. Pearse, Morton Coleman, Stephanie Lakritz, Adriana C Rossi, Ruben Niesvizky, Drew Ribadeneyra, John N. Allan, Karen Pekle, David Jayabalan, Tomer M Mark, Leora Boussi, Scott Ely, Brielle Liotta, Peter A. Forsberg
Publikováno v:
American journal of hematologyREFERENCES. 96(12)
Combination treatment regimens including a proteasome inhibitor (PI), an immunomodulatory agent (IMiD) and a corticosteroid are standards of care for initial treatment of multiple myeloma (MM). We aimed to evaluate if a sequential treatment program u
Autor:
David Jayabalan, Xiangao Huang, Samie R. Jaffrey, Liang Zhou, Ruben Niesvizky, Guoqiang Xu, Wenjun Yu
Publikováno v:
Frontiers in Cell and Developmental Biology
Frontiers in Cell and Developmental Biology, Vol 8 (2020)
Frontiers in Cell and Developmental Biology, Vol 8 (2020)
Cereblon (CRBN), a substrate receptor of cullin 4-RING E3 ligase (CRL4), mediates the ubiquitination and degradation of constitutive substrates and immunomodulatory drug-induced neo-substrates including MEIS2, c-Jun, CLC1, IKZF1/3, CK1α, and SALL4.